Oncology Pharma Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a ONPH research report →
Price Chart
About the company
Oncology Pharma Inc. is a pharmaceutical firm specializing in oncology, dedicated to the development, manufacturing, and commercialization of therapeutic agents. The company has a collaborative and licensing agreement with Kalos Therapeutics Inc.
- CEO
- George Malesek
- IPO
- 1994
- Employees
- 1
- HQ
- San Francisco, CA, US
Get TickerSpark's AI analysis on ONPH
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Similar companies
Peers in the same neighborhood.
- Market Cap
- $1.43M
- P/E
- -738.35
- PEG
- -7.38
- P/S
- 0.00
- P/B
- 3.45
- EV/EBITDA
- -359.20
- Div Yield
- 0.00%
- Gross Margin
- 0.00%
- Op Margin
- 0.00%
- Net Margin
- 0.00%
- ROE
- -1.08%
- ROIC
- -0.30%
Latest fiscal year · YoY change
- Revenue
- $0+0.0%
- Gross Profit
- $0+0.0%
- Op Income
- $-5,820
- Net Income
- $-5,820+0.0%
- EPS
- $0.00+0.0%
- OCF Growth
- +0.0%
- FCF Growth
- +0.0%
- 52W High
- $0.36
- 52W Low
- $0.00
- 50D MA
- $0.06
- 200D MA
- $0.04
- Beta
- -0.13
- RSI (14)
- 47
- Avg Volume
- 24.19K
No earnings-call transcripts are available for ONPH yet.
- Free Float
- 55.6%
- Shares Outstanding
- 27.39M
- Float Shares
- 15.22M
Our ONPH coverage
Recent articles, reports, and earnings notes.
No research on ONPH yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate ONPH report →Head to Head Comparison: Oncology Pharma (OTCMKTS:ONPH) & Rafael (NYSE:RFL)
defenseworld.net · Jul 28
Head-To-Head Survey: Oncology Pharma (OTCMKTS:ONPH) vs. Larimar Therapeutics (NASDAQ:LRMR)
defenseworld.net · Jan 18
Oncology Pharma, Inc. Has Engaged a PCAOB Audit Firm Looking Towards Moving the Company Towards a Senior Listing
accesswire.com · Oct 15
Oncology Pharma, Inc. Has Received the Committed Funding to Perform All Necessary IND-Enabling Preclinical Work for Its First Lead Candidate, a Dactinomycin Nanoemulsion Drug Product
accesswire.com · Sep 13
Oncology Pharma's Co-Development Agreement Pursues Strategic and Direct Objectives
accesswire.com · Aug 23
Oncology Pharma, Inc. Executes Co-Development Agreement with NanoSmart Pharmaceuticals, Inc.
accesswire.com · Aug 19
Oncology Pharma, Inc. To Move to Conducting Trials on Licensed IP
accesswire.com · Jul 20
Oncology Pharma, Inc. is Entering Into the Next Phase of its Growth and Expansion Phase
accesswire.com · Jun 30
Headlines from third-party outlets — TickerSpark isn't affiliated with these sources.